Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations.
about
Large-scale data integration framework provides a comprehensive view on glioblastoma multiformeNeural stem cells: brain building blocks and beyondIntegrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1Radioresistance of Brain TumorsIn vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studiesMouse models to interrogate the implications of the differentiation status in the ontogeny of gliomasFunctional roles and clinical values of insulin-like growth factor-binding protein-5 in different types of cancersMouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studiesSpecific visualization of glioma cells in living low-grade tumor tissueThe somatic genomic landscape of glioblastomaThe future role of personalized medicine in the treatment of glioblastoma multiformeHypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cellsTMEFF2 is a PDGF-AA binding protein with methylation-associated gene silencing in multiple cancer types including gliomaPerifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastomaAdvances in diagnostic and treatment modalities for intracranial tumors.Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multistep reactivation processBTECH: a platform to integrate genomic, transcriptomic and epigenomic alterations in brain tumorsCooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.An integrative characterization of recurrent molecular aberrations in glioblastoma genomes.microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma.Gene set based integrated data analysis reveals phenotypic differences in a brain cancer model.Bayesian methods for expression-based integration of various types of genomics data.Clinical relevance of tumor cells with stem-like properties in pediatric brain tumors.Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival.The interference of Notch1 target Hes1 affects cell growth, differentiation and invasiveness of glioblastoma stem cells through modulation of multiple oncogenic targetsNeuro-oncology: unmasking the multiforme in glioblastoma.GliomaPredict: a clinically useful tool for assigning glioma patients to specific molecular subtypes.PDGF-B-driven gliomagenesis can occur in the absence of the proteoglycan NG2Notch signaling in glioblastoma: a developmental drug target?Detecting independent and recurrent copy number aberrations using interval graphs.AKT pathway genes define 5 prognostic subgroups in glioblastoma.Inhibition of Notch signaling alters the phenotype of orthotopic tumors formed from glioblastoma multiforme neurosphere cells but does not hamper intracranial tumor growth regardless of endogene Notch pathway signatureGlioblastoma models reveal the connection between adult glial progenitors and the proneural phenotypehMOB3 modulates MST1 apoptotic signaling and supports tumor growth in glioblastoma multiforme.Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapiesActivated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivoRecruited cells can become transformed and overtake PDGF-induced murine gliomas in vivo during tumor progressionWhy is there a lack of consensus on molecular subgroups of glioblastoma? Understanding the nature of biological and statistical variability in glioblastoma expression data.Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells
P2860
Q21183973-A3A63DF7-9861-436C-BFCD-A56BFA126DB7Q24631889-54BA31CB-E3F0-456E-89D6-257CF8E22470Q24651548-4C2728E2-456B-4E2E-AEC0-78674CEC1EE9Q26752579-90BBA6F3-2D66-46CF-9254-D732B39652DDQ26820289-46CF5E65-018E-460B-954D-7C7596F62250Q26823340-DE0F86F6-7C0B-4A0C-B286-F37F80D098BCQ26830002-38D21901-7850-4D8D-A1A0-5714D307E15DQ27008537-0B03B833-C9BA-418C-B2BA-15E257B49C9BQ27324581-991448E7-EE7F-4E5F-8CCF-60190C9999A1Q28300185-516A36A8-EE6F-4B61-B337-3BECC5B6594FQ28391635-9A491E56-788E-4B4E-BA61-EA31F5AC6F26Q28393898-7A07E077-60E0-410D-85E0-F957571BCD65Q28740616-32F6AACD-5EDC-4E15-BE54-A136E4960AE9Q28743461-2BE33929-7C94-4A43-ACFD-DA53A2327A22Q30358150-B7FC9A64-A041-4B35-A271-8D5AE8B1729EQ30405908-DCD3B886-02B9-45E6-89E8-203A3A76EF09Q30484798-BA0E94A0-1EB6-4118-B65B-CA846C677B64Q30545759-BF76B118-A311-4670-AF47-4AA55F593611Q30551524-71A1933D-1C90-4984-A2F1-3DD47E910CA0Q30570563-68766374-C976-4050-A175-96EBBBF1D0A4Q30656585-D9886541-92A7-4F4A-BC36-E0EB64368D27Q30668548-E943E9BB-CCA1-4313-B006-C85A3AE607C7Q30997872-B1C9A8DE-B9EA-4F77-AE7D-54506BAE1BB6Q31016728-1D39BBCD-1908-42DD-B886-D0A86AD59663Q33566723-7CD6D2FA-5416-4B9D-98FA-7CA01A857346Q33597721-61BB6685-CE10-43E8-B72E-0583E8C4A92EQ33633443-FAF2B0A0-99CF-4CB1-AEFF-691B74F3CEBFQ33715843-8C30F302-129D-4D62-AE0C-EBA19D222D35Q33747041-E31C4A70-5362-4671-BE0E-D81D92506808Q33760431-169F1129-1705-4130-88EE-361F98D1DB25Q33830769-1B0EEB4D-2D4B-44E6-AA34-7AC3CCAF3A92Q33911184-FFE7E9D3-F39A-4849-8B7A-685FEB897F48Q33916126-96EB6B1D-0285-408F-90FE-2F23B69BD51BQ33916556-DD9844C0-20FF-462B-AB7D-C73264009252Q33925544-66796F98-E204-4250-9930-A71CECC2A38AQ33945972-6A06F17F-8952-4D6C-8CC3-F338765BE630Q33960280-40956C8C-D8BE-4945-AE94-F9A2CFE7F43DQ33987614-47332F63-D314-4980-9880-D674CC4A0055Q33992432-032C5CC8-FE78-4963-8176-DA3887683707Q34000666-50650408-ABD0-4115-A3F9-4B2E7B120E38
P2860
Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Glioblastoma subclasses can be ...... ssociated genomic alterations.
@ast
Glioblastoma subclasses can be ...... ssociated genomic alterations.
@en
type
label
Glioblastoma subclasses can be ...... ssociated genomic alterations.
@ast
Glioblastoma subclasses can be ...... ssociated genomic alterations.
@en
prefLabel
Glioblastoma subclasses can be ...... ssociated genomic alterations.
@ast
Glioblastoma subclasses can be ...... ssociated genomic alterations.
@en
P2093
P2860
P1433
P1476
Glioblastoma subclasses can be ...... ssociated genomic alterations.
@en
P2093
Adesh Tandon
Alicia Pedraza
Dolores Hambardzumyan
Eric Holland
Hiroyuki Momota
Tatsuya Ozawa
P2860
P356
10.1371/JOURNAL.PONE.0007752
P407
P577
2009-11-13T00:00:00Z